

Programme

Thursday, July 2

ORAL SESSIONS

09.00–10.30

11.00–12.30

PL4 Plenary: Consequences of an Evolving Epidemic

Chairs: Michael H. Merson, Heydee Pellegrini
Venue: Arena
Time: 09.00–10.30

- 485 From personal to global survival
Javier Luis Hourcade Belloque
486 From personal to global survival
Naisiadet Maina
487 Priorities for public funds: crises in national leadership?
Omwony Ojwok
488 Priorities for public funds: crises in national leadership?
Marina Mahathir
489 Human rights: consequences for the epidemic HIV
Mary Robinson

PPL4 Plenary: Biomedical Advances in HIV Research

Chairs: Kim Nichols, F. Waldvogel
Venue: Session Hall I
Time: 09.00–10.30

- 490 How viruses cause immunosuppression
Rolf Zinkernagel
491 The significance of virus subtypes for epidemiology and pathogenesis
Jaap Goudsmit
492 How HIV functions, multiplies and causes disease:
possible new approaches to therapy
Robert Gallo

(H) (P)

A41 Vaccine Trials in Humans

Chairs: Vina Churdboonchart, Andrei Kozlov
Venue: Session Hall VII
Time: 11.00–12.30

- 493 Vaccine trials in humans
Larry Corey
494 Induction of immune responses
Kent Weinhold
495 CD8+CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost
Thomas Evans, L. Corey; M.L. Clements-Mann; K. Weinhold; R.B. Belshe; J.L. Exler; A.M. Duliege, USA*
496 A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120
Michael C. Keefer, M.J. McElrath; K. Weinhold; G.J. Gorse; M. Mulligan; D. Francis; D. Panicali, USA*
497 HIV-1 cross-clade lymphoproliferative responses following immunization with recombinant Gp120 SF2
Thippawan Chuanchitra, S. Ratto-Kim; M. De Souza; K. Rungruangthanakit; S. Nitayaphan; C. Khamboonruang; C. Chuanchitra; R.A. Michael; F. Sinangil; A.M. Duliege; J.G. McNeil; D.L. Birx, Thailand*
498 NIAD funding opportunities for AIDS vaccine research: new strategy and programmes
Steve Bende

(P)

JULY
2

NOTES

ORAL SESSIONS

11.00–12.30

11.00–12.30

B41 Care in Special Populations

Chairs: Shaun Mellors, Robert Shearer
 Venue: Session Hall III
 Time: 11.00–12.30

499	Virologic response to antiretroviral therapy among HIV-infected injection drug users <i>Wafa El-Sadr*; Sharon Mannheimer; J. Flowers; H. Safavi; J. Curtis, USA</i>	32407
500	Barriers to HIV antiretroviral therapy among injection drug users in settings with and without universal health insurance coverage <i>David Celentano*; R.S. Hogg; D. Vlahov; S.A. Strathdee; R.D. Moore; A. Palepu; S. Cohn, USA</i>	42285
501	Prisons and public health: Emerging issues in HIV treatment adherence <i>Linda Frank, USA</i>	32408
502	Continuity of medical care and risk of incarceration in HIV+ and HIV- high risk women <i>Mary Sheu*; Timothy Flanigan; T.P. Flanigan; J. Allsworth; J. Hogan; M.D. Stein; D. Vlahov; E. Schoenbaum, USA</i>	32411
503	Health status and co-morbidity of HIV+ and HIV-out-of-treatment injection drug users (IDUs) <i>Frederick Altice*; K. Khaoshnoon; K.M. Blankenship; C.T. Roan; M. Kravitz, USA</i>	32409
504	Pozfit, positively fit: A prospective, pilot project in community-based HIV rehabilitation services <i>Gerry Bally*; G.R. Murphy, Canada</i>	42400
505	Palliative care for HIV-infection in a skilled nursing facility <i>Peter A. Selwyn*; K.P. Fennie; S. Molde; J. Constantino, Sr.; P. Wetherill; L. Goldman; C. Kennedy, USA</i>	22427

B42 Predictors of Response to Antiretroviral Treatment

Chairs: Jonathan Anderson, Peter Mugenyi
 Venue: Session Hall IV
 Time: 11.00–12.30

506	HIV RNA, CD4+ cell count, and immune activation markers predict HIV-related wasting prior to AIDS in the Multicenter AIDS Cohort Study (MACS) <i>Robert H. Lyles*; A.M. Tang; J.W. Mellors; J.B. Margolick; B.R. Visscher; J.P. Phair; N.M.H. Graham, USA</i>	32167
507	HIV serum RNA, CD4 cell numbers and risk for clinical endpoints in a case-cohort study of ACTG 175 <i>David Katzenstein*; S. Kim; M. Hughes; S. Hammer; V. Degruttola, USA</i>	12124
508	Phosphorylation rate of 3"-azidothymidine in maternal and fetal peripheral blood mononuclear cells at term <i>Riad Agbaria*; J. Barak; E. Manor; J. Balzarini, Israel</i>	42258
509	Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced HIV+ patients <i>P.G. Hoggard*; David J. Back; S.E. Gibbons; J. Lloyd; M.G. Barry; S.H. Khoo; C. Loveday, UK</i>	42260
510	The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma <i>Richard M.W. Hoetelmans*; M.H.E. Reijers; G.F. Weberling; S. Furriaans; F.M.A. Lange, The Netherlands</i>	42259
511	Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period <i>Richard M.W. Hoetelmans*; R.P.G. Heeswijk, Van; P.L. Meenhorst; F.W. Mulder; W.A. Scheele; F.H. Beijnen, The Netherlands</i>	42261
512	Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir (IDV) <i>Patricia W.H. Hugen*; D.M. Burger; R.M.W. Hoetelmans; K. Brinkman; P.L. Meenhorst; J.W. Mulder; P.P. Koopmans, The Netherlands</i>	32330

B43 HIV-infection in Children

Chairs: Luke Chipperfield, Connie Mwaise Osborne
 Venue: Arena
 Time: 11.00–12.30

513	Markers for diagnosis and for monitoring therapy in children <i>John Ziegler</i>
514	Clinical management in the North <i>Sandra Burchett</i>
515	Clinical management in resource-poor settings <i>Suniti Solomon</i>
516	Palliative care for children <i>Jim Oleske</i>

C41 Trends and Patterns of HIV Epidemics

Chairs: Jordi Casabona, Euclides Castilho
 Venue: Session Hall V
 Time: 11.00–12.30

517	HIV-infection in young men in Northern Thailand, 1991–1997, increasing role of injection drug use <i>Kenrad Nelson*; S. Eittrakul; D.D. Celentano; C. Beyrer; S. Kuntolbutra; C. Khambonruang, USA</i>	43555
518	Epidemiology of HIV-1 seroconversion among young adults in the U.S. Army, 1985–1996: Current trends in an evolving epidemic <i>Philip Renzullo*; H. Bacellar; R.P. Garner; D.L. Birx; J.G. McNeil, USA</i>	13212
519	Risk for HIV-1 seroconversion in the Ugandan people's defense forces <i>Kathleen George*; D. Hom; J. McGrath; J.L. Johnson; P. Mugenyi; R. Mugerwa; J. Ellner, Uganda</i>	23507
520	Annual HIV incidence decreased among persons with sexually transmitted diseases (STD) in Italy between 1988 and 1994 <i>Barbara Suligoi*; M. Giuliani; M. Balducci; N. Galai, Italy</i>	13281
521	HIV in the Philippines: Analysis of data from the National HIV Sentinel Surveillance System <i>Maria Consoria Lim-Quizon*; M.C.R. Roces; W. Cuenco; A.E. Ghee; G. Poumerol; S. Omi, Philippines</i>	43508
522	The HIV/AIDS epidemic in Europe: Changing trends and new challenges <i>Francoise F. Hamers*; A.M. Downs; A. Infuso; J.B. Brunet, France</i>	13179

ORAL SESSIONS

11.00–12.30

11.00–12.30

C42 STD/HIV Interaction

Chairs: Subhash Hira, Judy Wasserheit
 Venue: Session Hall VI
 Time: 11.00–12.30

G

523	Overview of the STD-HIV interaction <i>King Holmes</i>	23372
524	Population attributable risk of HIV incidence associated with STD symptoms, Rakai Community-Based Study, Uganda <i>Maria J. Wawer*, N.K. Sewankambo; D. Serwadda; L. Paxton; N. Kiwanuka; C.J. Li; R.H. Gray, USA</i>	33238
525	STD control for HIV prevention in the US: Is there likely to be an impact? <i>William Kassler*, K.L. Irwin; M.L. Kamb; H. Weinstock; R.W. Steketee; M. St. Louis; J. Wasserheit, USA</i>	23369
526	Estimating the effect of treating sexually transmitted diseases (STDs) on HIV transmission <i>Richard Rothenberg*, J. Wasserheit; M. St. Louis, USA</i>	23347
527	Heterosexual and perinatal transmission of HIV-1: Associations with bacterial vaginosis (BV) <i>Taha Taha*, N. Kumwenda; G. Liomba; J. Chiphangwi; D. Hoover; G. Dallabetta; P. Miotti, USA</i>	23276

C43 Rapid Assessment for Intervention Development

Chairs: Thierry E. Mertens, Gerald V. Stimson
 Venue: Satellite Hall 2000
 Time: 11.00–12.30

D41 Human Rights and Legal Challenges

Chairs: Ian Kramer, Miriam Maluwa
 Venue: Session Hall I
 Time: 11.00–12.30

G H

534	Developing the human rights program for the AIDS prevention council in Jalisco, Mexico <i>Armando J. Diaz Camarena*, Jesus Martinez Serna; Juana Martinez Lopez; Ancira Dueñas Martinez; Carmen Cardona Aldrete; Patricia Campos Lopez, Mexico</i>	44145
535	Training HIV-positive people to document human rights violations in Asia: The APN + human rights initiative <i>Susan Paxton*, B. White, Australia</i>	44133
536	Access to treatment: AIDS affected population in Costa Rica wins constitutional challenge <i>Antonio Matamoros*, L.G.M. Murillo Guillermo; M.F.G. Garita Manuel; M.C.R. Marco Castillo, Costa Rica</i>	44104
537	Promoting the rights of prisoners: Condoms, bleach, needles, methadone and care in prisons <i>Ralf E.F. Jürgens, Canada</i>	44191
538	A human rights approach to reducing women's vulnerability to HIV/AIDS <i>Daniel Whelan, USA</i>	44148
539	Creation of an enabling and gender just legal environment as a prevention strategy for the spread of HIV/AIDS amongst women <i>Mandeep Dhaliwal, India</i>	44164

JULY
2**D42 Workplace – Promotion, Prevention and Protection**

Chairs: Richard Constant Okuv, Anthony Pramvalratana
 Venue: Session Hall II
 Time: 11.00–12.30

D42 Workplace – Promotion, Prevention and Protection

Chairs: Richard Constant Okuv, Anthony Pramvalratana
 Venue: Session Hall II
 Time: 11.00–12.30

529	Rapidly responding to HIV and AIDS – Can social science inform community and international interventions? <i>Chris Fitch*, G.V. Stimson; T. Rhodes; A. Ball; G. Weiler; R. Sujata; A. Morue; A. Perez-Gomez, UK</i>	24178
530	Mekong movements: Border areas HIV/AIDS prevention project <i>Glooi Tran Minh*, L.A. Esposito Catherine; O. Souksavanh, Vietnam</i>	43237
531	Situation analysis of prostitution in Bobo Dioulasso, Burkina Faso and vulnerability of the sex workers in the context of the HIV epidemic <i>Michel Cartoux*, P. Huygens; M.D. Nikiema; G. Ido; A. Dembele; P. Van De Perre, Burkina Faso</i>	43290
532	Effectiveness of peer education and monitoring of the condom use by the sex workers in brothel settings in Bangladesh for prevention of HIV <i>Ankhi Begum*, M.A. Quddus; F.K. Chowdhury; Swarup Sarkar; M. Bloem; Nazrul Islam, Bangladesh</i>	33521
533	Peer education to reduce STI/HIV transmission in Mutare, Zimbabwe <i>Simon Mashababe*, D. Mclean; R. Gomo; D. Wilson; R. Sabatier, Zimbabwe</i>	33516

540	Peer education among factory workers in Zimbabwe; providing a sustainable HIV prevention intervention <i>David Katzenstein*, W. McFarland; M. Mbizvo; A. Latif; R. Machekano; J. Parsonnet; M. Bassett, USA</i>	33514
541	AIDS, India and the trucking industry <i>Barun Kanjilal*, S. Forsythe, India</i>	44200
542	Protecting paradise: Tourism and AIDS in the Dominican Republic <i>Steven Forsythe*, J. Hasbún; M. Butler De Lister, UK</i>	44239
543	UK coalition back to work pilot project <i>Bec Clarkson, UK</i>	24288
544	Sexual networking and AIDS awareness program at the workplace: the case of oil locations in Nigeria <i>Bode-Law Faleiyimu*, O.A. Fagade; S.O. Ogundutti; A.I. Faleiyimu; L.A. Ubuane, Nigeria</i>	43230
545	Grief at work: helping organizations cope with AIDS-related loss <i>Stuart Gibson*, A. Plotnick; D. Scott, USA</i>	24243

Skills Building workshops 11.00–14.30: see page 00 for details

NOTES

ORAL SESSIONS

13.00–14.30

13.00–14.30

A42 Animal Models for Vaccine Development

Chairs: Sam Avrett, Reinhard Kurth
Venue: Session Hall III
Time: 13.00–14.30

- | | | |
|-----|---|-------|
| 546 | Attenuated SIV vaccines: Safety and efficacy following heterologous challenge
<i>Mark G. Lewis*; F. Nembre; R. Desrosiers; Y. Lu; E. Rud; V. Hirsch; D. Birx, USA</i> | 11238 |
| 547 | Role of b-chemokines in protective immunity against intrarectal SIVsm challenge of macaques
<i>Rigmor Thorstensson*; R. Ahmed; C. Wilson; P. Putkonen; Y. Wang; T. Lehner; G. Biberfeld, Sweden</i> | 11239 |
| 548 | Recombinant vaccine-induced protection against the highly pathogenic SIVmac251 dependence on route of challenge exposure
<i>Geneoveffa Franchini, USA</i> | 21200 |
| 549 | Protective T-cell mediated immunity induced by a consecutive HIV-1 DNA and avipox vaccine regimen
<i>Stephen Kent*; A. Zhao; E.M. Dax; J.D. Chandler; H.L. Robinson; D.B. Boyle; I.A. Ramshaw, Australia</i> | 21198 |
| 550 | Potent neutralization of primary HIV-1 isolates by antisera induced upon immunization with a recombinant protein expressing the native V1/V2 domain of gp120
<i>Abraham Pinter*; O. Trochev; W.J. Hornen; Z. Wu; S. Reiken; M. Lewis; S.C. Kayman, USA</i> | 21194 |
| 551 | Multi-subtype envelope-based DNA and protein immunization strategies for broadening immune responses to HIV-1
<i>Susan W. Barnett*; Y. Sun; H.S. Legg; T.C. VanCott; J.R. Mascola; F.M. Sinangil, USA</i> | 21196 |

A43 Pre-Clinical Drug Development

Chairs: D.J. Back, T. Smart
Venue: Session Hall VII
Time: 13.00–14.30

- | | | |
|-----|---|-------|
| 552 | Introduction
<i>J. Condra</i> | |
| 553 | S-1153, a new nonnucleoside reverse transcriptase inhibitor of HIV-1
<i>Tamio Fujiwara*; A. Sato; M. El-Farrash; Y. Wu; L. Chen; M. Hatanaka; Y. Hiruma, Japan</i> | 41181 |
| 554 | Cellular pharmacology of the antiviral agents PMPA and PMEA in vitro and in vivo
<i>Arnold Fridland*; B. Robbins; J. Rodman; C.C. Tsai; N. Bischofberger, USA</i> | 41175 |
| 555 | A resistance surmountable HIV protease inhibitor effective against both wild-type and new analogs of HIV-1 protease
<i>Yoshiaki Kiso*; M. Kishida; H. Matsumoto; S. Mizumoto; T. Kimura, Japan</i> | 41212 |
| 556 | Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis
<i>Jenae Limoges*; D.R. McClelland; Y. Persidsky; J. Rasmussen; E.R. Lanier; J. Reinhard; H.E. Gendelman, USA</i> | 11233 |
| 557 | Anti-HIV activity, biochemistry, and pharmacokinetics of b-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D-D4FC)
<i>Raymond Schinazi*; L. Ma; J. Shi; D. Liotta; A. Faraj; J.P. Sommadossi, USA</i> | 41174 |

B44 Neurological Complications of HIV

Chairs: Paola Cinque, Christina M. Marra
Venue: Session Hall IV
Time: 13.00–14.30

- | | | |
|-----|---|-------|
| 558 | Latest developments in neuropathogenesis
<i>To be confirmed</i> | |
| 559 | Animal models of HIV neuropathogenesis
<i>Dominique Dormont</i> | |
| 560 | Predictive markers for HIV-associated dementia and sensory neuropathy
<i>Elizabeth Childs*; Justin C. McArthur; R.H. Lyles; E. Miller; B.A. Cohen; B.B. Chen; J. Mellors; J.C. McArthur, USA</i> | 32191 |
| 561 | Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (Study CNAB 3001)
<i>Bruce James Brew*; S.J. Brown; J. Catalan; N. Sacktor; M. Halman; W.T. Symonds; C. Romero; CNAB 3001 Study Team, Australia</i> | 32192 |
| 562 | Progressive multifocal leukoencephalopathy (PML) treatment with cidofovir
<i>Rustam Al-Shahi*; M. Sadler; E. Davies; M.R. Nelson; B.G. Gazzard, UK</i> | 32193 |
| 563 | Evidence for independent development of RT inhibitor (RTI) resistance patterns in cerebrospinal fluid (CSF) compartment
<i>Philip Cunningham*; D. Smith; C. Satchell; D.A. Cooper; B.J. Brew, Australia</i> | 32284 |
| 564 | Stavudine stops neuro-AIDS in AZT-non-responders
<i>Gabriele Arendt*; H.-J. v. Giesen; H. Jablonowski, Germany</i> | 32207 |

B45 Bridging Session: Issues in Clinical Trial Design

Chairs: Lynda Dee, Markus Flepp
Venue: Arena
Time: 13.00–14.30

- | | | |
|-----|--|--|
| 565 | What kinds of trials?
<i>Ann Coller</i> | |
| 566 | The role of cohort studies
<i>Andrew Phillips</i> | |
| 567 | Trials in developing countries
<i>Praphan Phanuphak</i> | |
| 568 | The patients' perspective
<i>James Kreppner</i> | |

P

ORAL SESSIONS

13.00–14.30

13.00–14.30

C44	Transgender Issues: Living with HIV, Prevention, Identity	G
Chairs:	Camille Cabral, Julian Hows	
Venue:	Session Hall V	
Time:	13.00–14.30	

569	Implications of living with HIV/AIDS as a transitioning transsexual woman <i>Danny Anderson, Canada</i>	14208
570	HIV-infection among transsexual sex workers from developing countries. A review of six years of activity of a reference center in Rome <i>Laura Spizzichino*, P. Gattari; M. Zaccarelli Mauro; S. Venezia; G. Rezza, Italy</i>	23534
571	The HIV hormone bridge: Connecting impoverished HIV+ transsexual sex workers to HIV medical care <i>James Grimaldi*, J. Jacobs, USA</i>	44225
572	The health care issues of the HIV+ and HIV- incarcerated transgendered community <i>Scott Cozza, USA</i>	43417
573	The Portuguese transgender community: an unknown reality <i>Maria Jose Campos*, Jó Bernardo; G. Machado; G. Tavares; K. Wandolly; G. Salce, Jr.; G. Diniz, Portugal</i>	43267
574	Mobilizing transgenders for HIV prevention through cultural presentation <i>Jose Sescon*, Alfeo Salcedo, Philippines</i>	23530

C45	Model-Based Evaluation of HIV Prevention Programmes	
Chairs:	Jane Galvao, Edward Kaplan	
Venue:	Session Hall VI	
Time:	13.00–14.30	
575	Patterns of participation in mass STD treatment: Model-aided evaluation of impact on HIV incidence <i>Eline Korenromp*, C. Van Villet; A. Gayvole; H. Grosskurth; R.H. Hayes; J.D.F. Habbema, The Netherlands</i>	43476
576	Potential public health impact of offering post-exposure prophylaxis (PEP) for episodic high-risk sexual behaviour by men who have sex with men (MSM) <i>Grant Colfax*, E. Vittinghoff; K. MacQueen; J. Douglas; D. McKirnan; F. Judson; S. Buchbinder, USA</i>	33183
577	The effects of two years of harm reduction in Rome <i>Marina Davoli*, Annette Verster; Teresa Spadea; Fabio Patruno; Fulvia Pascualini; Carlo Alberto Perucci; Massimo Arcà, Italy</i>	33391
578	Cost effectiveness of an HIV/AIDS peer education programme among commercial sex workers (CSW): results from Cameroon <i>Lilani Kumaranyake*, P. Mangtani; A. Boupda-Kuate; J.C. Foumena Abada; C. Cheta; Z. Njoumemi; Watts, UK</i>	33592
579	Interaction of vaccine effectiveness and risky behaviour <i>Sally Blower</i>	
580	HIV counselling and testing in Tanzania and Kenya is cost-effective: Results from the voluntary HIV counselling and testing study <i>Michael Sweat*, G. Sangiwa; D. Balmer, USA</i>	33277

C46	HIV and Drug Injection: A World of Epidemics	G
Chairs:	Genci Mucollari, Swarup Sarkar	
Venue:	Satellite Hall 2000	
Time:	13.00–14.30	

581	Outbreaks of HIV-infections among Russian injecting drug users <i>Irena Savchenko, Russia</i>	
582	HIV/AIDS risk in non-hospitalized injection drug users in Japan <i>Timothy Sankary*, H. Ohashi; K. Soda, USA</i>	23183
583	Trend of HIV incidence among drug users in an HIV epicenter in Northern Thailand, 1989–1997 <i>Somsak Supawitkul*, P. Saksoong; P. Sawanpanyalert; S. Piyaworawong; H. Yanai, Thailand</i>	23198
584	Decline in a very large HIV epidemic: Injecting drug users in New York City, 1991–1996 <i>Don C. Des Jarlais*, R. Friedman Samuel; Theresa Perlis; Deren Sherry; Lucia Torian; Denise Paone; Michael Marmor, USA</i>	23216
585	HIV prevalence among female injecting drug users (IDU) in London, 1990 to 1996 <i>Ali Judd*, G.M. Hunter; G.V. Stimson, UK</i>	23214

D43 What We Are Told About AIDS: Media Response and Transformation

Chairs:	Bunmi Makinwa, Simon Watney	
Venue:	Session Hall I	
Time:	13.00–14.30	

586	Media impact/agreement between a NGO and a national newspaper. A successful experience of collaboration <i>Alejandro Brito*, A. Diaz; C. Bonfil; M. Figueroa; M. Zozaya, Mexico</i>	34219
587	Sensitizing print media to AIDS and reproductive health issues <i>Sadhna Mohan, India</i>	33447
588	Developing a nationwide public service advertising on STD syndromes <i>Kathleen Cabal*, J. Fleras; C. Aquino; N. Villar, Philippines</i>	33450
589	Using ethnic media to reach multiple language migrant communities in the Sydney region <i>Tadgh McMahon, Australia</i>	33445
590	Assessment of Moscow press participation in HIV/AIDS prevention <i>Elena V. Lioubaeva*, Vadim V. Pokrovsky, Russia</i>	33449
591	Trends of reporting on HIV/AIDS and mobile groups in the print media of Bangladesh. Can the media be an ally in altering the image of AIDS? <i>Joachim Victor Gomes*, Elora Barua; M. Bloem, Bangladesh</i>	34215

NOTES

D44 Mental Health and HIV		G	A44 Cellular Immunity		G
Chairs:	V.Sonnenberg-Schwan, Sussa Szabo		Chairs:	Fernando Aiuti, Angel Jaramillo	
Venue:	Session Hall II		Venue:	Session Hall III	
Time:	13.00–14.30		Time:	15.00–17.00	
592	Counselling strategies: they work! Results from the Voluntary HIV Counselling and Testing (VCT) Study <i>Don Balmer*: Olga Grinstead; E. Van Praag; S. Gregorich; G. Sangiwa; C. Furlonge; USA</i>	24321	598	Control of HIV replication requires virus-specific helper and CTL function and levels of CTL activity are in equilibrium with viral burden <i>Spyros Kalams*: S.P. Buchbinder; M.J. Billingsley; E.S. Rosenberg; N. Jones; A.K. Trohla; B.D. Walker, USA</i>	31130
593	Confidentiality and couple HIV counselling encourage client disclosure of serostatus and risk behaviour: Results from the voluntary HIV counselling and testing study <i>Olga Grinstead*, A. Van Der Staten; G. San Giwa; M. Hogan; USA</i>	24323	599	HIV-specific cytotoxic T lymphocytes (CTLs) in Thai exposed uninfected (EU) female sex workers (FSWs) are directed to multiple regions of HIV-1 subtype E <i>Busarawari Sriwanthan*; K.B. Bond; T.W. Hodge; C.P. Pau; T.D. Mastro; N.L. Young; K. Limpakarnjanarat, USA</i>	31120
594	Psychosocial differences in European and African HIV-positive women <i>Catherine Bungener*, N. Marchard-Gonod; F. Bricaire, France</i>	24150	600	HIV-1 specific cytotoxic T-lymphocyte responses in uninfected Kenyan prostitutes: Behavioural and immunologic correlates <i>Rupert Kaul*, K. Fowke; E. Njagi; J. Rutherford; K.S. MacDonald; F.A. Plummer, Kenya</i>	31123
595	Psychological and neuropsychological predictors of mortality and disease progression in HIV-1 infection <i>Jose Catalan*, A.J. Champion; T. Baldeweg; B. Gazzard, UK</i>	13345	601	Cross-clade envelope Gp160, Gag p55 and pol specific CD8+ CTL responses early following HIV-1 clade-B infection <i>Susan Wilson*, S.L. Pedersen; J.C. Kunich; G. Mazzara; J. Tartaglia; C.L. Celum; H.W. Sheppard, USA</i>	31122
596	Serious mental illness among HIV-infected Medicaid patients in New Jersey <i>Stephen Crystal*, James Thomason Walkup; Usha Sambamoorthi, USA</i>	24222	602	Cross-clade cytotoxic T cell response to HIV-1 proteins among HLA disparate North Americans and Thais <i>Julia Lynch*, M. Desouza; M. Robb; S. Nitayaphan; L. Markowitz; D. Birx; J. Cox, USA</i>	31128
597	The personal meanings and constructs attributed to being labelled with AIDS dementia complex <i>Irit Ben-Nissan*, K. O'Neill; B. Bren, Australia</i>	24254	603	New HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte (CTL) epitopes identified in studies of Thai HIV-infected female sex workers <i>Kyle Bond*, B. Sriwanthan; T.W. Hodge; C.P. Pau; A.S. Degroot; B.M. Jesdale; T.D. Mastro; N.L. Young; K. Limpakarnsanarat; J.M. McNicholl, USA</i>	31127
			604	HIV-specific cytotoxic T lymphocytes (CTL) in HIV-1 infected children: CTL recognition of various HIV clades <i>Yves Riviere*, F. Bus Eyne; M.L. Chaix; B. Fleury; S. Blanche; C. Rouzioux, France</i>	31132
			605	Increased levels of b-chemokines and antigen specific T-cell proliferation in HIV-2 exposed non-infected individuals in Guinea-Bissau <i>Sören Andersson*: O. Larsen; F. Dias; A. Naucler; P. Aaby; R. Thorstensson; G. Biberfeld, Sweden</i>	31133

NOTES



Pathway Symbol:

G Gender

ORAL SESSIONS

15.00–17.00

15.00–17.00

C47 Tuberculosis and HIV in Developing Countries

Chairs: Peter Godfrey-Faussett, Nkanda Luo
 Venue: Session Hall IV
 Time: 15.00–17.00

- 609 The impact of HIV on transmission of tuberculosis (TB) in Ugandan households
*David Guwatudde**; *M.K. Nakeeto*; *P. Musoke*; *C. Whalen*; *G. Bukenya*; *A. Okwera*; *J. Ellner*, *Uganda* 13258
- 610 Trends of HIV-1 infection among pulmonary tuberculous adults, 1993–1997, Kampala, Uganda
*Alphonse Okwera**; *H. Luzze*; *P. Nsubuga*; *J.L. Johnson*; *C. Whalen*; *R. Mugerwa*; *J. Ellner*, *Uganda* 13273
- 611 Increasing frequency of TB among staff in a South African hospital: Impact of the HIV epidemic on supply of health care
*David Wilkinson**; *C.F. Gilks*, *South Africa* 13246
- 612 Multiple tuberculosis episodes in HIV-infected individuals: Is there a need for secondary chemoprophylaxis?
*Samuel E. Kalluvya**; *E.N. Mkumbo*; *M. Shindano*, *Tanzania* 13277
- 613 The impact of HIV-infection on tuberculosis control: A prospective cohort study of African patients
*Pamela Sonnenberg**; *J. Murray*; *S.C.P. Shearer*; *P. Godfrey-Faussett*, *South Africa* 13259
- 614 Evaluating community contribution to effective tuberculosis care in high HIV prevalence populations
*Dermot Maher**; *E. Nyarko*, *Switzerland* 13276
- 615 Multidrugs resistant TB (MRTB): Study of an outbreak in HIV patients
*Oscar GarciaMecina**; *M. Ambroggi*; *G. Ortega*; *S.M. Oliva*; *L. Redini*; *S. Poggi*; *J. Benetucci*, *Argentina* 13274
- 616 HIV-infection and TB associated with injecting drug use and resistant M.tb, Bangkok, Thailand 2HIV/AIDS Collaboration, Nonthaburi; 3CDC & HIV/AIDS Collaboration, Nonthaburi; Thailand
*Juree Punnotok**; *U. Pumprug*; *T. Naiwatanakul*; *N. Shaffer*; *P. Supannachat*; *C. Choochotthaworn*; *P. Ponglerthapagorn*, *Thailand* 13264

B46 HIV-Associated Neoplasia

Chairs: Alexandra M. Levine, Andres Schmilovich
 Venue: Session Hall VII
 Time: 15.00–17.00

- 617 Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS)
*Sara Santambrogio**; *A.L. Ridolfo*; *N. Tosca*; *M. Galli*; *C. Parravicini*; *M. Corbellino*, *Italy* 22275
- 618 Topical 9-cis-Retinoic acid PanretinT gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: Interim results of an international, placebo-controlled trial (ALRT 1057-503)
*Neil Bodsworth**; *On Behalf of the International Panretin KS Study Group Intern*, *Australia* 22277
- 619 North American phase 3 study (protocol L1057T-31) of PanretinT gel (LGD1057, ALRT1057) for cutaneous AIDS-related Kaposi's sarcoma
*Alvin Frie Dman-Kien**; *M. Conant*, *USA* 22283
- 620 HHV-8, proliferation, apoptosis and ploidy in epidemic (AKS), endemic (EKS), and classical (CKS) Kaposi's sarcoma (KS)
*Epahata Kaaya**; *Peter Biberfeld*; *E. Castanous-Velez*; *T. Heden*; *M. Stuzl*; *J.Z. Zou*; *J.N. Kitinya*, *Sweden* 22282
- 621 Association of vitamin A deficiency with cervical dysplasia in the Women's Interagency HIV Study (WIHS)
*Audrey French**; *M.H. Cohen*; *R.O. Semba*; *J.K. Burke*; *K.M. Weber*; *L.S. Massad*, *USA* 22301
- 622 Case-control study of cervical cancer and HIV-infection in Abidjan, Côte d'Ivoire
*Georgette Adjorlolo-Johnson**; *A. Anhoux*; *K. Toure-Coulibaly*; *G. Laruche*; *G. Aissi*; *E. Unger*; *M. Honde*; *S. Vernon*; *A.E. Greenburg*; *S.Z. Wiktor*, *Côte d'Ivoire* 22305
- 623 Incidence of squamous intraepithelial lesions (SIL) in HIV-infected women
*Marie-Christine Delmas**; *A. Agarossi*; *C. Bergeron*; *F. Meier*; *J. Paavonen*; *J.D. Poveda*; *J.A.R. Van Den Hoek*, *France* 22306
- 624 Comparison of the amount of HPV 16 DNA in cervicovaginal secretions of HIV-infected and uninfected women, using quantitative competitive-polymerase chain reaction (QC-PCR)
*Thomas Wright**; *X.W. Sun*; *T.V. Ellerbrock*; *Chiasson*, *USA* 22311

JULY
2**B47 Grand Rounds: Clinical Case Studies**

Chairs: David Chipanta, Michel P. Glauser
 Venue: Arena
 Time: 15.00–17.00

- 625 Case presentations
Amalia Telenti
- 626 Virologic failure
Joep Lange
- 627 Treatment complications
Robert Schooley
- 628 A case of HIV-infection in the developing world
Sin Yew Wong
- 629 Natural history of HIV-associated disease under HAART
Diane Havlir

ORAL SESSIONS

15.00–17.00

15.00–17.00

G **P****C48 Bridging Session: Microbicides: Towards a New Paradigm**Chairs: Lori Heise, Joseph Perriens
Venue: Session Hall V
Time: 15.00–17.00

- 630 Economic and marketing issues
Lieve Fransen
631 State-of-the-art: clinical research
Zeda Rosenberg
632 Pre-clinical overview: what possibilities exist
Mark Wainberg
633 Case study for political advocacy: Zimbabwe
Priscilla Misihairabwi
634 Discussant: trials
Gita Ramjee
635 Discussant: consumer perspective
Kanokwan Gaye Tharawan
636 Discussant: government perspective
Debra Birnkrant

G**D45 Implications of New Treatments at Individual and Population Level**Chairs: Enzio Dos Santos Filho, C. Perez
Venue: Session Hall I
Time: 15.00–17.00

- 637 AIDS, virtually normal now? Protease inhibitors and the end of consensus
Meurieystyn Horton, UK 44183
638 Do people fail drugs, or do drugs fail people? The discourse of "adherence"
Agnes Harley, J.D. Davids; J.M. Maskovsky; J.S. Shull, USA* 34212
639 T.H.E. (Tools for Health and Empowerment) course: A unique disease management program
W. David Hardy, Ebere Igoboko; M.M.L. Rice; K. Anastos; E.F. Igoboko; R. Torres; P.J. Welch; S.D. Goodwin, USA* 34236
640 The impacts of combination therapies on the lives of people with HIV
Peter Weatherburn, W. Anderson; F.C.I. Hickson; P.G. Keogh, UK* 24260
641 Treatments, intimacy and disclosure in the sexual practice of HIV-infected adults in Australia
Michael Bartos, D. Ezzy; K. McDonald; D. O'Donnell; R. de Visser, Australia* 23402
642 HIV/AIDS preventive attitudes and behaviour of French and Swiss gay men in the era of new treatments. A comparison of two national surveys
Phillipe Adam, F. Moreau-Gruet; F. Hamers; M.C. Delmas; J.B. Brunet; F. Dubois-Arber, France* 34107
643 HAART, attitudes, and risk behaviour among serodiscordant male couples
Robert H. Remien, G. Wagner; A. Carballo Dieguez; C. Dolezal, USA* 14136
644 New therapies for HIV and sexual risk behaviour among gay men in London, UK
Graham Bolding, Jonathan Elford; L. Sherr; M. Maguire; J. Elford, UK* 23106

P**D46 Resource Mobilisation: Where Will the Money Come From?**Chairs: Sally Cowall, Sofia Mukaso-Monico
Venue: Session Hall II
Time: 15.00–17.00

- 645 Sustainability beyond donor aid
Soledad Atayan, Philippines 44220
646 The Global Business Council on HIV/AIDS (GBC)
Jose Llados, Ben Plumley; J. Hussey, UK* 44223
647 Amounts, patterns and trends of national and international financing of the response to HIV/AIDS in developing countries, 1996–1997
Daniel Tarantola; G. Ernberg, USA* 44232
648 European funding for HIV in the developing world
Jan Pronk
649 North American Funding for HIV in the developing world
Steve Morin
650 Funders concerned about AIDS on philanthropic funding
Paul di Donato
651 A unique Zululand industry joint venture response to the needs of employees with HIV/AIDS
Jennifer Rogers, South Africa 44221

SKILLS BUILDING WORKSHOPS

SB41 Gestión clínica en contextos de recursos limitados (en español)

Venue: Room E
Time: 11.00–14.30

La escasez de recursos en el Sur supone un reto a la hora de actuar en los casos de VIH. Mediante el formato de grandes rondas clínicas, los participantes analizarán temas tales como la monitorización de infecciones, el tratamiento de infecciones oportunistas, la utilización de terapias antirretrovirales y cuidados paliativos. El objetivo de esta sesión es el de proporcionar las técnicas necesarias para evaluar el desarrollo apropiado de una acción en el tratamiento clínico. Este taller está dirigido al personal clínico y del área de la salud, y a las personas afectadas por el VIH.

*Impartido por: Ezio Tavora dos Santos Filho, Grupo Pela Vida, Brazil;
José Gatell, Hospital Clinic of Barcelona, Spain; Patty Garcia, National AIDS Control
Programme, Peru. Carlos del Rio, Emory University, USA*

SB 42 Building Strategic Alliances to Help Sustainable Programme and Organisational Impact

Venue: Room F
Time: 11.30-14.00

Most organisations face financial constraints. Although donor funding may be available to start a programme what happens when a project changes, or the funding decreases or ends? A rising demand for funding for both prevention and care programmes has emphasised the need to assess existing patterns of resource use and to explore alternative ways of sustaining programmes. One way organisations can work towards sustaining effective programmes is by building alliances, or actively collaborating with other organisations, not only NGOs and donors but the private sector, church, local and national government. This workshop will focus on helping participants plan a strategy to develop working relationships/alliances.

Facilitated by: Evelyn Gacad, Philippines HIV/AIDS NGO Support Programme, Philippines; Supanya Lamsam, International HIV/AIDS Alliance, Thailand; Sarah Lee, International HIV/AIDS Alliance, UK; Geoff Manthey, UNAIDS, Philippines/Australia

SB 43 Développement de programmes de diététique dans les contextes défavorisés en ressources (en français)

Venue: Room G
Time: 11.30-14.00

Pour beaucoup de personnes vivant avec le VIH/sida, la seule thérapie d'accès relativement simple reste la nutrition. À travers cet atelier, les participants tenteront de dégager des stratégies pratiques afin de mettre en place des programmes de nutrition en mesure de répondre aux besoins des personnes vivant avec le VIH/sida dans des milieux défavorisés. On recommande aux personnes vivant avec le VIH/sida ainsi qu'aux formateurs et au personnel médical d'assister à cet atelier.

Facilitated by: George Carter, Direct AIDS Alternative Information Resources, USA;
Maquette Ndiaye, BASICS/USAID, Senegal

SB 44 Clinical Management in Resource-Poor Settings

Venue: Room H
Time: 11.30-14.00

The limited resources in the South present challenges in responding clinically to HIV. Using a clinical grand rounds format, participants will explore issues of monitoring the infection, managing opportunistic infections, using antiretroviral therapies, and palliative care. This session is designed to provide skills in assessing appropriate courses of action in clinical management. Clinicians, health care providers and persons affected by HIV are encouraged to attend.

Facilitated by: Tuti Merati, Citra Usadh, Indonesia; Elly Katabira, Makere University, Uganda; Mark Ottenweller, Soweto Hope, South Africa/USA

SB 45 Basic Evaluation Techniques for Programmes and Organisations

Venue: Room I
Time: 11.30–14.00

Evaluation helps project staff understand and respond to programme and organisational weaknesses, as well as highlight organisational effectiveness and programme impact. This workshop will introduce basic techniques of evaluation. Through the use of case studies, participants will develop an evaluation strategy and understand how to relate evaluation results to both improve their programmes and respond to donor demands. This workshop is aimed at those wanting to learn basic evaluation techniques.

Facilitated by: Kamanee Hapugalle, Alliance, Sri Lanka; Timothy Frasca, Corporacion Chilena de Prevencion del Sida, Chile; Penny Bardsley, Argyll and Bute NHS Trust, UK

SB 46 The Wonders of E-mail

Venue: Room K
Time: 11.00–12

Electronic communication allows people to link with individuals and organisations all over the world, and is an important communication and networking tool. Join us to learn the basics, including how to send and receive mail, manage E-mail files and address books, and HIV/AIDS related discussion fora.

Coordinated by: Francisco Mingorance; Tim France and Norbert Ayer, Fondation du Present, Switzerland; M. David Haerry, Sida Info Doc Suisse, Switzerland

SB 47 E-mail: les merveilles du courrier électronique (en français)

Venue: Room K
Time: 13.00–14.30

La communication électronique permet un contact direct avec des individus ou des organisations à travers le monde entier. Il s'agit aussi d'un outil important pour le réseautage et la communication. Joignez-vous à nous dans cet atelier pour apprendre les bases, y compris comment envoyer et recevoir du courrier électronique, gérer des fichiers et un carnet d'adresses électroniques, et avoir accès à des forums de discussions concernant le VIH/sida.

Coordinated by: Fondation du Présent, Switzerland Sida Info Doc Suisse, Switzerland

NOTES

POSTER SESSIONS

Track A 41101–41130

Track A: Basic Science

- 41101 Interactions of secretory IgA with HIV-1 gp120: Potential pitfalls of anti-HIV ELISA using saliva
Susan Jackson, S.J. Prince; R. Kulhavy; J. Mestecky, USA*
- 41102 HIV-screening with the Elecsys automated analyser: Combined testing for anti-HIV and HIVAg within 18 minutes
Frédéric Donie, B. Upmeier; E. Hoess; E. Faatz, Germany*
- 41103 Detection of memory T cells in HIV+ individuals: Cytokine producing lymphocyte precursors (CPLp)
Kendall A. Smith, G. Chiocchia; F. Pilaro; E.L. Jacobson; R. Emert, USA*
- 41104 Universal peptide for detection of HIV-1 group M and group O infections in rapid immunoassay
Afzal Chowdhury, J.M. Lovchik; M.A. Childs; D. Bernstein, USA*
- 41105 Evaluation of a locally produced particle agglutination assay for detection of antibodies to HIV-1
Wilfred James Njoroge, C.W. Mutura; W.A. Mwangi; N. Sakagami; K. Kakimoto; P.M. Tupei; T. Kurimura, Japan*
- 41106 Murex HIV-1.2.0 is a highly sensitive and specific assay for antibodies to HIV-1/M, HIV-1/O and HIV-2
Richard Bristow, T. Carter; K. Francis; J. Lovell; B. Rodgers; D. Trotter; P. Weston, UK*
- 41107 Detection of HIV-1 Subtypes by a new rapid immunochromatographic test
Hiroyasu Arai, S. Devare; T. Kosaka; K. Takeda, Japan*
- 41108 Validation study of HIV testing in urine samples
David Mabey, John Changalucha; B. West; D. Ross; R. Balira; J. Todd; T. Boerma; D. Mabey, UK*
- 41109 Predictors of HIV-infection among professional blood donors with Western Blot Indeterminate results (WBI)
Usha K. Baveja, D. Chattopadhyaya; R.K. Aggarwal; V. Doda; S. Kumari; J. Sokhey, India*
- 41110 HIV antibody actity measurement how to distinguish primoinfected from old infected patients using one ELISA test adapted to AXSYM Automate
Christopher Paxan; A. Lemeur; B. Evreux; S. Kouyoumdjian; J-M. Chennecault; F. Lunel
- 41111 Identification of a new virus-associated epitope inducing antibody responsible for the non-progression to AIDS
Pascale Galea, C.R. Steinhart; P. Willem; N. Profizi; C. Lecontel; J.C. Chermann, France*
- 41112 In vitro "HIV-1 antibody induction. Testing of the "Shiloo" Tube
Carmen Soler Claudi, C. Gomez Palomino; T. Jehuda-Cohen, Mexico*
- 41113 A new generation of HIV-diagnostic assay: Results of the evaluation of the Enzymun-Tests HIV combi
Eluke Faatz, F. Donie; W. Melhior; B. Upmeier; C. Seidel, Germany*
- 41114 Performance of calypte HIV-1 urine EIA in three us populations
Dean Schoer, V. Mitteco; T. Gottfried; M. Kanar, USA*
- 41115 Performance of an HIV-1, HIV-2 and HIV-1 group O immunoassay on the Abbott ARCHITECTT 2000 analyzer
William Black, S. Stewart; A. Hoffman; J. Prostko; L. Xu, USA*
- 41116 A new approach to flow cytometry-based CD4 T-cell enumeration for absolute and percentage values
Michèle Bergeron, F.F. Mandy; T. Ding; S. Phaneuf, Canada*
- 41117 Sensivity evaluation of Vironostika Uni-Form II plus O with samples from Thailand
Thippawan Chuenchitra, Thailand
- 41118 HIV-screening with the Elecsys automated analyser: Testing for HIVAg within 18 minutes with a sensitivity of 3 pg/ml
Urban Schmitt, D. Schlieper; B. Upmeier; W. Melchior; E. Faatz, Germany*
- 41119 Anti HIV1/2 mass testing, what should be done?
Alexandre M. Oliveira, C.C. Hofling; M.C. Ramos; S.A.A. Chaves, Brazil*
- 41120 Rapid, 3rd generation one-step immunoassay for HIV antibodies, useful in developing countries
Jesus Benitez; O. Ganzo; J. Rivero; J. Gavilondo, Cuba
- 41121 Seroprevalence of HIV-infection among street children in Maiduguri Edemenang D. Okpudo-Itata*, T.O. Harry; M. Bulterys; A. Abimiku, Nigeria
- 41122 Sensitivity of HIV-1 group M Western blot for the confirmation of HIV-1 group O infections, according to different interpretation criteria
Charlotte Ngansop, Seraphin Kuate; L. Zekeng; M. Kengne; L. Kaptue, Cameroon*
- 41123 Prevalence and control of STDs/HIV among commercial sex workers (CSW)
Jyotsna Shrestha, V.L. Gurubacharya, Nepal*
- 41124 Modifications in the DTH reaction in HIV-infected individuals
Kamen Plochev, Bulgaria
- 41125 Evaluation of a fast method (HIVSAV+) for serologic diagnosis of HIV-1 e 2
Draurio Barreira, G. Silva; H.M.V. Oliveira; Y. Bravin, Brazil*
- 41126 Immunological monitoring in HIV-infection
Yuri Mitin, E.I. Zmushko; A.N. Malkov, Russia*
- 41127 Field evaluation of the HIV-1 Amplicor Monitor and NucliSens quantitative HIV-1 RNA PCR assay in persons infected with HIV-1 subtype A in Abidjan, Côte d'Ivoire
John Nkenga Song, M. Kalou; C. Bile; M.Y. Borget; M. Morokro; E.R. Ekpin; P. Ghys; A.E. Greenberg; S.Z. Wiktor, Côte d'Ivoire*
- 41128 Comparative evaluation of amplicor HIV-1 monitor with added primer set with quantiplex v2.0 HIV RNA assay and the nuclisens for quantitation of HIV-1 RNA in a Thai study population, primarily infected with subtype E
Sasiwimol Ubolyam, K. Ruxrungham; G.J. Weverling; C. Ungsidhapand; J. Lange; D. Cooper; P. Phanuphak, Thailand*
- 41129 High throughput assay for sensitive detection of HIV-1 RNA of diverse origins, including type O strains
Cristina Giachetti, D. Kolk; J. Dockter; J.P. Knowlton; R. Wang; S. Hotaling; S. McDonough, USA*
- 41130 Sensitivity, linear range and performance of HIV-1 subtypes of the COBASAMPLICOR HIV-1 monitor test
Cynthia Pletcher, D. De Bonville; J. Wang; K. Lavallee; A. Chutoransky; K. Arch; A. Wang, USA*